About the Authors

Kevin ten Haaf

k.tenhaaf@erasmusmc.nl (KtH); rmeza@umich.edu (RM)

Affiliation Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands

Jihyoun Jeon

Affiliation Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America

Martin C. Tammemägi

Affiliation Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada

Summer S. Han

Affiliations Department of Radiology, Stanford University, Palo Alto, California, United States of America, Department of Medicine, Stanford University, Palo Alto, California, United States of America

Chung Yin Kong

Affiliation Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

Sylvia K. Plevritis

Affiliation Department of Radiology, Stanford University, Palo Alto, California, United States of America

Eric J. Feuer

Affiliation Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America

Harry J. de Koning

Affiliation Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands

Ewout W. Steyerberg

Affiliation Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands

Rafael Meza

k.tenhaaf@erasmusmc.nl (KtH); rmeza@umich.edu (RM)

Affiliation Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America

Competing Interests

HJdK and KtH are members of the Cancer Intervention and Surveillance Modeling Network (CISNET) Lung working group (grant 1U01CA199284-01 from NIH). HJdK is the principal investigator of the Dutch-Belgian Lung Cancer Screening Trial (Nederlands-Leuvens Longkanker Screenings onderzoek; the NELSON trial). KtH is a researcher affiliated with the NELSON trial. HJdK and KtH received a grant from the University of Zurich to assess the cost-effectiveness of computed tomographic lung cancer screening in Switzerland. HJdK took part in a 1-day advisory meeting on biomarkers organized by M.D. Anderson/Health Sciences during the 16th World Conference on Lung Cancer. HJdK and KtH were involved in a Health Technology Assessment study for CT Lung Cancer Screening in Canada (dr. Paszat, Cancer Care Ontario). MCT is the developer of the PLCOm2012 lung cancer risk prediction model. Use of the model is free of charge to all non-commercial users of the PLCOm2012, whether clinical or personal use. MCT has assigned the commercial intellectual property rights to Brock University. Part of the net proceeds from Brock University’s commercial licensing of use of the PLCOm2012 is to be paid to MCT. To date no such payments have been made to or received by MCT. At Cancer Care Ontario, MCT is Senior Scientist and Scientific Lead for the High Risk Lung Cancer Screening Pilot Studies, which plan to begin recruitment in April 2017. Recruitment will be based on lung cancer risk estimated by the PLCOm2012. Cancer Care Ontario is the agency representing Ontario’s Ministry of Health and Long-Term Care for cancer screening and is a not-for-profit organization. Neither Cancer Care Ontario nor MCT will receive any funds for use of the PLCOm2012 in the pilot studies or subsequently if lung cancer screening of high-risk individuals is expanded across Ontario. MCT was an invited speaker at the following meetings in which the PLCOm2012 model was discussed and MCT travel expenses were in part paid for. In none of these presentations did the total expenses paid for exceed the actual total costs, i.e., MCT did not financially benefit from the presentation. 1. MCT, Invited speaker: Selection Criteria for Lung Cancer Screening – Incidence versus Mortality Models. Cancer Intervention and Surveillance Modeling Network (CISNET) meeting, Ann Arbor, Michigan, 6 May 2013. 2. MCT, Invited speaker: Modeling Lung Cancer Risk, In Symposium: Lung Cancer Screening: Moving Forward, and Looking Forward. American Thoracic Society (ATS) Annual Meeting. May 17-22, 2013, Philadelphia, Pennsylvania. 3. MCT, Invited speaker: Lung Cancer Screening, In Symposium: High-Risk Populations and Cancer Screening. American Society for Clinical Oncology (ASCO) Annual Meeting. June 1-4, 2013, Chicago, Illinois. 4. MCT, Invited speaker: Risk Stratification for Lung Cancer Screening Studies. In session: Low-dose computed lung screening. At the 15th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. October 28, 2013, Sydney, Australia. 5. MCT, Invited speaker: Screening for lung cancer. At the Canadian Lung Cancer Conference. 7 February 2014, Vancouver, BC. 6. MCT, Invited speaker: Lung Cancer Screening – Issues & Updates. 9th Ontario Thoracic Cancer Conference. Niagara-on-the-Lake. 26 April 2014. 7. MCT, Invited speaker: Risk models for selection of individuals for lung cancer screening. Pan-Canadian Lung Cancer Screening Meeting Montreal, QC. 29 May 2014. 8. MCT, Invited speaker: Lung cancer risk models for targeting screening. Cancer Intervention and Surveillance Modeling Network (CISNET) meeting. Minneapolis, MN. June 2, 2014. 9. MCT, Invited speaker: Selection of Individuals for Lung Cancer Screening. McMaster University – Juravinski Cancer Center – Regional Oncology Rounds. Hamilton, ON. 13 November 2014. 10. MCT, Invited speaker: Lung cancer risk and screening. Cancer Intervention and Surveillance Modeling Network (CISNET) annual meeting. Bethesda, MD. December 10, 2014. 11. MCT, Invited speaker: National Academy of Sciences, Institute of Medicine, National Cancer Policy Forum, Workshop – Implementation of Lung Cancer Screening. Identifying High-Risk Populations for Screening: Risk Modeling – Current Ideas, New Developments, and Future Potentials. June 20-21, 2016, Washington, D.C.

Author Contributions

Conceptualization: KtH JJ MCT SSH CYK SKP EJF HJdK EWS RM. Data curation: KtH JJ RM. Formal analysis: KtH JJ MCT EWS RM. Funding acquisition: CYK SKP EJF HJdK RM. Methodology: KtH JJ MCT EWS RM. Software: KtH JJ MCT EWS RM. Supervision: MCT CYK SKP EJF HJdK EWS RM. Visualization: KtH JJ MCT EWS RM. Writing – original draft: KtH. Writing – review & editing: KtH JJ MCT SSH CYK SKP EJF HJdK EWS RM.